Gene · 7006
Papers1,477
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 1,477
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Roles of STAT3 in the pathogenesis and treatment of glioblastoma. | Front Cell Dev Biol | 2023 | 36923251 | PubTator, text mining | PubMed |
| Blood Coagulation and Beyond: Position Paper from the Fourth Maastricht Consensus Conference on Thrombosis. | Thromb Haemost | 2023 | 36913975 | PubTator, text mining | PubMed |
| Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines. | Invest New Drugs | 2023 | 36913160 | PubTator, text mining | PubMed |
| Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases. | J Med Chem | 2023 | 36912866 | PubTator, text mining | PubMed |
| New insights into the Lck-NF-κB signaling pathway. | Front Cell Dev Biol | 2023 | 36910149 | PubTator, text mining | PubMed |
| Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials. | Molecules | 2023 | 36903645 | PubTator, text mining | PubMed |
| The Development of Emotion Understanding among Five- and Six-Year-Old Left-Behind Children in Rural China. | Int J Environ Res Public Health | 2023 | 36900984 | PubTator, text mining | PubMed |
| Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics. | PLoS One | 2023 | 36897912 | PubTator, text mining | PubMed |
| Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma. | PLoS One | 2023 | 36888611 | PubTator, text mining | PubMed |
| Effective extraction of polyribosomes exposes gene expression strategies in primary astrocytes. | Nucleic Acids Res | 2023 | 36881761 | PubTator, text mining | PubMed |
| Asymmetric reconstruction of the aquareovirus core at near-atomic resolution and mechanism of transcription initiation. | Protein Cell | 2023 | 36856784 | PubTator, text mining | PubMed |
| Biochemical Studies of Systemic Lupus Erythematosus-Associated Mutations in Nonreceptor Tyrosine Kinases Ack1 and Brk. | Biochemistry | 2023 | 36854171 | PubTator, text mining | PubMed |
| Mechanosensitive Ion Channels and Their Role in Cancer Cells. | Membranes (Basel) | 2023 | 36837670 | PubTator, text mining | PubMed |
| Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study. | Medicina (Kaunas) | 2023 | 36837525 | PubTator, text mining | PubMed |
| Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma. | Antioxidants (Basel) | 2023 | 36830087 | PubTator, text mining | PubMed |
| Novel Bruton's tyrosine kinase inhibitor TAS5315 suppresses the progression of inflammation and joint destruction in rodent collagen-induced arthritis. | PLoS One | 2023 | 36821545 | PubTator, text mining | PubMed |
| Integrated TTF and self-determination theories in higher education: The role of actual use of the massive open online courses. | Front Psychol | 2023 | 36818124 | PubTator, text mining | PubMed |
| Strategy toward Kinase-Selective Drug Discovery. | J Chem Theory Comput | 2023 | 36815703 | PubTator, text mining | PubMed |
| B-lymphoid tyrosine kinase-mediated FAM83A phosphorylation elevates pancreatic tumorigenesis through interacting with β-catenin. | Signal Transduct Target Ther | 2023 | 36797256 | PubTator, text mining | PubMed |
| Signaling pathways in rheumatoid arthritis: implications for targeted therapy. | Signal Transduct Target Ther | 2023 | 36797236 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7006/papers?page=10